ruptured intracranial aneurysm
Conditions
Interventions
Intervention group:deferasirox
Control group:normal saline
Sponsors
Yuebei People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.The age range is 18-65 years old, first-ever aneurysmal ASH; 2.World Federation of Neurosurgical Societies Subarachnoid Hemorrhage Classification(WFNS SAH)= 2; The time interval between symptom onset and hospitalization is <= 24 hours (the time interval between symptom onset and drug intervention is <= 72 hours); 4.Interventional embolization of aneurysms within 48 hours after symptom onset; 5.The ruptured aneurysm must undergo interventional embolization before enrollment, with a Raymond Roy score of 1 (complete) or 2 (residual neck) after embolization; 6.Before intervention, patients can cooperate with head CT examination; 7.After surgery, patients can undergo imaging and laboratory tests; 8.The patient or their immediate family members agree to join this study and sign an informed consent form;
Exclusion criteria
Exclusion criteria: 1.Trauma, vascular malformation, dissecting aneurysm or fusiform aneurysm associated subarachnoid hemorrhage; 2.Patients with multiple aneurysms who are unable to identify the ruptured aneurysm or have a prior history of ruptured cerebral aneurysms. 3.Individuals who have experienced a stroke within the week prior to admission and may be at risk of cerebral vasospasm; 4.Individuals who have previously undergone intracranial vascular stent implantation, intracranial aneurysm embolization or clipping surgery; 5.Individuals with severe extrabrain diseases (such as severe pneumonia, sepsis, complex urinary tract infections, severe liver and kidney dysfunction, and severe hypertension); 6.Individuals with significant intracranial diseases (such as Moyamoya disease, central nervous system vasculitis, severe fibromuscular dysplasia, arteriovenous malformations, arteriovenous fistulas, severe intracranial artery stenosis, malignant brain tumors); 7.Serious comorbidities that may confuse research results (such as patients with multiple sclerosis, dementia, severe depression, multiple system organ failure, epilepsy); 8.Compared with the CT scan at admission, patients with new cerebral infarction or significantly increased cerebral hemorrhage, significantly aggravated cerebral edema, or cerebral herniation after surgery; 9.Long term use of immunosuppressive therapy; Recent major bleeding or major surgery (such as open multiple fractures, large artery surgery); Individuals with existing neurological dysfunction due to other factors; 10.Pregnant women or individuals with allergic constitution (moderate or above allergy history) or any degree of iron chelator allergy;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Montreal Cognitive Assessment Scale and Improved Rankin Scale Scoring; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood and cerebrospinal fluid ferritin content;Hippocampal morphology and cerebral iron deposition;Blood routine, liver and kidney function; | — |
Countries
China
Contacts
Public ContactZhongqing Huang
Yuebei People's Hospital
Outcome results
None listed